WEST PHARMACEUTICAL SERVICES (WST) Fundamental Analysis & Valuation

NYSE:WST • US9553061055

235.46 USD
+4.37 (+1.89%)
At close: Mar 13, 2026
235.46 USD
0 (0%)
After Hours: 3/13/2026, 8:04:00 PM

This WST fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

6

Taking everything into account, WST scores 6 out of 10 in our fundamental rating. WST was compared to 57 industry peers in the Life Sciences Tools & Services industry. WST gets an excellent profitability rating and is at the same time showing great financial health properties. While showing a medium growth rate, WST is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

7

1. WST Profitability Analysis

1.1 Basic Checks

  • In the past year WST was profitable.
  • In the past year WST had a positive cash flow from operations.
  • In the past 5 years WST has always been profitable.
  • In the past 5 years WST always reported a positive cash flow from operatings.
WST Yearly Net Income VS EBIT VS OCF VS FCFWST Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

1.2 Ratios

  • With an excellent Return On Assets value of 11.56%, WST belongs to the best of the industry, outperforming 92.98% of the companies in the same industry.
  • Looking at the Return On Equity, with a value of 15.54%, WST belongs to the top of the industry, outperforming 89.47% of the companies in the same industry.
  • WST has a better Return On Invested Capital (14.09%) than 92.98% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for WST is above the industry average of 11.85%.
Industry RankSector Rank
ROA 11.56%
ROE 15.54%
ROIC 14.09%
ROA(3y)13.53%
ROA(5y)15.35%
ROE(3y)18.17%
ROE(5y)20.93%
ROIC(3y)15.83%
ROIC(5y)17.92%
WST Yearly ROA, ROE, ROICWST Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5 10 15 20 25

1.3 Margins

  • WST's Profit Margin of 16.06% is amongst the best of the industry. WST outperforms 84.21% of its industry peers.
  • In the last couple of years the Profit Margin of WST has remained more or less at the same level.
  • Looking at the Operating Margin, with a value of 20.53%, WST belongs to the top of the industry, outperforming 87.72% of the companies in the same industry.
  • WST's Operating Margin has been stable in the last couple of years.
  • Looking at the Gross Margin, with a value of 35.91%, WST is doing worse than 61.40% of the companies in the same industry.
  • In the last couple of years the Gross Margin of WST has remained more or less at the same level.
Industry RankSector Rank
OM 20.53%
PM (TTM) 16.06%
GM 35.91%
OM growth 3Y-7.75%
OM growth 5Y1.08%
PM growth 3Y-7.51%
PM growth 5Y-0.08%
GM growth 3Y-3.01%
GM growth 5Y0.08%
WST Yearly Profit, Operating, Gross MarginsWST Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10 20 30 40

8

2. WST Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), WST is creating some value.
  • Compared to 1 year ago, WST has less shares outstanding
  • Compared to 5 years ago, WST has less shares outstanding
  • Compared to 1 year ago, WST has an improved debt to assets ratio.
WST Yearly Shares OutstandingWST Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M
WST Yearly Total Debt VS Total AssetsWST Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B 4B

2.2 Solvency

  • An Altman-Z score of 12.14 indicates that WST is not in any danger for bankruptcy at the moment.
  • The Altman-Z score of WST (12.14) is better than 98.25% of its industry peers.
  • WST has a debt to FCF ratio of 0.44. This is a very positive value and a sign of high solvency as it would only need 0.44 years to pay back of all of its debts.
  • Looking at the Debt to FCF ratio, with a value of 0.44, WST belongs to the top of the industry, outperforming 92.98% of the companies in the same industry.
  • A Debt/Equity ratio of 0.06 indicates that WST is not too dependend on debt financing.
  • WST has a Debt to Equity ratio of 0.06. This is in the better half of the industry: WST outperforms 64.91% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF 0.44
Altman-Z 12.14
ROIC/WACC1.29
WACC10.96%
WST Yearly LT Debt VS Equity VS FCFWST Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B

2.3 Liquidity

  • WST has a Current Ratio of 3.02. This indicates that WST is financially healthy and has no problem in meeting its short term obligations.
  • The Current ratio of WST (3.02) is comparable to the rest of the industry.
  • WST has a Quick Ratio of 2.34. This indicates that WST is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 2.34, WST is in line with its industry, outperforming 54.39% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.02
Quick Ratio 2.34
WST Yearly Current Assets VS Current LiabilitesWST Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B

4

3. WST Growth Analysis

3.1 Past

  • The Earnings Per Share has been growing slightly by 8.00% over the past year.
  • The Earnings Per Share has been growing by 8.94% on average over the past years. This is quite good.
  • WST shows a small growth in Revenue. In the last year, the Revenue has grown by 6.25%.
  • Measured over the past years, WST shows a small growth in Revenue. The Revenue has been growing by 7.44% on average per year.
EPS 1Y (TTM)8%
EPS 3Y-5.25%
EPS 5Y8.94%
EPS Q2Q%12.09%
Revenue 1Y (TTM)6.25%
Revenue growth 3Y2.12%
Revenue growth 5Y7.44%
Sales Q2Q%7.51%

3.2 Future

  • Based on estimates for the next years, WST will show a quite strong growth in Earnings Per Share. The EPS will grow by 9.50% on average per year.
  • The Revenue is expected to grow by 5.60% on average over the next years.
EPS Next Y11.14%
EPS Next 2Y11.07%
EPS Next 3Y11.63%
EPS Next 5Y9.5%
Revenue Next Year6.01%
Revenue Next 2Y6.04%
Revenue Next 3Y6.31%
Revenue Next 5Y5.6%

3.3 Evolution

  • The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
WST Yearly Revenue VS EstimatesWST Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 1B 2B 3B 4B
WST Yearly EPS VS EstimatesWST Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2 4 6 8 10

3

4. WST Valuation Analysis

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 32.30, WST can be considered very expensive at the moment.
  • 63.16% of the companies in the same industry are more expensive than WST, based on the Price/Earnings ratio.
  • When comparing the Price/Earnings ratio of WST to the average of the S&P500 Index (25.70), we can say WST is valued slightly more expensively.
  • The Price/Forward Earnings ratio is 29.06, which means the current valuation is very expensive for WST.
  • 61.40% of the companies in the same industry are more expensive than WST, based on the Price/Forward Earnings ratio.
  • When comparing the Price/Forward Earnings ratio of WST to the average of the S&P500 Index (23.84), we can say WST is valued slightly more expensively.
Industry RankSector Rank
PE 32.3
Fwd PE 29.06
WST Price Earnings VS Forward Price EarningsWST Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of WST indicates a somewhat cheap valuation: WST is cheaper than 70.18% of the companies listed in the same industry.
  • WST's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. WST is cheaper than 63.16% of the companies in the same industry.
Industry RankSector Rank
P/FCF 36.17
EV/EBITDA 20.01
WST Per share dataWST EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30 40

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates WST does not grow enough to justify the current Price/Earnings ratio.
  • The decent profitability rating of WST may justify a higher PE ratio.
PEG (NY)2.9
PEG (5Y)3.61
EPS Next 2Y11.07%
EPS Next 3Y11.63%

6

5. WST Dividend Analysis

5.1 Amount

  • WST has a yearly dividend return of 0.32%, which is pretty low.
  • Compared to an average industry Dividend Yield of 0.10, WST pays a better dividend. On top of this WST pays more dividend than 84.21% of the companies listed in the same industry.
  • Compared to an average S&P500 Dividend Yield of 1.82, WST's dividend is way lower than the S&P500 average.
Industry RankSector Rank
Dividend Yield 0.32%

5.2 History

  • The dividend of WST has a limited annual growth rate of 5.48%.
  • WST has paid a dividend for at least 10 years, which is a reliable track record.
  • WST has not decreased their dividend for at least 10 years, which is a reliable track record.
Dividend Growth(5Y)5.48%
Div Incr Years32
Div Non Decr Years34
WST Yearly Dividends per shareWST Yearly Dividends per shareYearly Dividends per share 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0.2 0.4 0.6 0.8

5.3 Sustainability

  • WST pays out 12.40% of its income as dividend. This is a sustainable payout ratio.
  • WST's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP12.4%
EPS Next 2Y11.07%
EPS Next 3Y11.63%
WST Yearly Income VS Free CF VS DividendWST Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M
WST Dividend Payout.WST Dividend Payout, showing the Payout Ratio.WST Dividend Payout.PayoutRetained Earnings

WST Fundamentals: All Metrics, Ratios and Statistics

WEST PHARMACEUTICAL SERVICES

NYSE:WST (3/13/2026, 8:04:00 PM)

After market: 235.46 0 (0%)

235.46

+4.37 (+1.89%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)02-12
Earnings (Next)04-22
Inst Owners97.62%
Inst Owner Change-2.08%
Ins Owners0.33%
Ins Owner Change0.38%
Market Cap16.96B
Revenue(TTM)3.07B
Net Income(TTM)493.70M
Analysts80.87
Price Target328.99 (39.72%)
Short Float %3.13%
Short Ratio2.33
Dividend
Industry RankSector Rank
Dividend Yield 0.32%
Yearly Dividend0.85
Dividend Growth(5Y)5.48%
DP12.4%
Div Incr Years32
Div Non Decr Years34
Ex-Date04-29
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)12.82%
Min EPS beat(2)10.24%
Max EPS beat(2)15.4%
EPS beat(4)4
Avg EPS beat(4)15.68%
Min EPS beat(4)10.24%
Max EPS beat(4)20.68%
EPS beat(8)7
Avg EPS beat(8)12.16%
EPS beat(12)11
Avg EPS beat(12)11.7%
EPS beat(16)14
Avg EPS beat(16)11.27%
Revenue beat(2)2
Avg Revenue beat(2)0.72%
Min Revenue beat(2)0.33%
Max Revenue beat(2)1.1%
Revenue beat(4)4
Avg Revenue beat(4)1.63%
Min Revenue beat(4)0.33%
Max Revenue beat(4)4.33%
Revenue beat(8)7
Avg Revenue beat(8)1.11%
Revenue beat(12)8
Avg Revenue beat(12)0.49%
Revenue beat(16)10
Avg Revenue beat(16)0.34%
PT rev (1m)-6.91%
PT rev (3m)-5.85%
EPS NQ rev (1m)1.65%
EPS NQ rev (3m)1.77%
EPS NY rev (1m)3.22%
EPS NY rev (3m)3.47%
Revenue NQ rev (1m)2.4%
Revenue NQ rev (3m)2.48%
Revenue NY rev (1m)-0.24%
Revenue NY rev (3m)-0.21%
Valuation
Industry RankSector Rank
PE 32.3
Fwd PE 29.06
P/S 5.52
P/FCF 36.17
P/OCF 22.47
P/B 5.34
P/tB 5.54
EV/EBITDA 20.01
EPS(TTM)7.29
EY3.1%
EPS(NY)8.1
Fwd EY3.44%
FCF(TTM)6.51
FCFY2.77%
OCF(TTM)10.48
OCFY4.45%
SpS42.68
BVpS44.1
TBVpS42.47
PEG (NY)2.9
PEG (5Y)3.61
Graham Number85.05
Profitability
Industry RankSector Rank
ROA 11.56%
ROE 15.54%
ROCE 17.45%
ROIC 14.09%
ROICexc 18.03%
ROICexgc 18.82%
OM 20.53%
PM (TTM) 16.06%
GM 35.91%
FCFM 15.25%
ROA(3y)13.53%
ROA(5y)15.35%
ROE(3y)18.17%
ROE(5y)20.93%
ROIC(3y)15.83%
ROIC(5y)17.92%
ROICexc(3y)20.32%
ROICexc(5y)23.97%
ROICexgc(3y)21.34%
ROICexgc(5y)25.37%
ROCE(3y)19.61%
ROCE(5y)22.21%
ROICexgc growth 3Y-13.74%
ROICexgc growth 5Y-3.06%
ROICexc growth 3Y-13.28%
ROICexc growth 5Y-2.17%
OM growth 3Y-7.75%
OM growth 5Y1.08%
PM growth 3Y-7.51%
PM growth 5Y-0.08%
GM growth 3Y-3.01%
GM growth 5Y0.08%
F-Score7
Asset Turnover0.72
Health
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF 0.44
Debt/EBITDA 0.26
Cap/Depr 166.8%
Cap/Sales 9.3%
Interest Coverage 2103.33
Cash Conversion 94.07%
Profit Quality 94.98%
Current Ratio 3.02
Quick Ratio 2.34
Altman-Z 12.14
F-Score7
WACC10.96%
ROIC/WACC1.29
Cap/Depr(3y)224.35%
Cap/Depr(5y)223.25%
Cap/Sales(3y)11.53%
Cap/Sales(5y)10.68%
Profit Quality(3y)73.64%
Profit Quality(5y)69.18%
High Growth Momentum
Growth
EPS 1Y (TTM)8%
EPS 3Y-5.25%
EPS 5Y8.94%
EPS Q2Q%12.09%
EPS Next Y11.14%
EPS Next 2Y11.07%
EPS Next 3Y11.63%
EPS Next 5Y9.5%
Revenue 1Y (TTM)6.25%
Revenue growth 3Y2.12%
Revenue growth 5Y7.44%
Sales Q2Q%7.51%
Revenue Next Year6.01%
Revenue Next 2Y6.04%
Revenue Next 3Y6.31%
Revenue Next 5Y5.6%
EBIT growth 1Y7.88%
EBIT growth 3Y-5.8%
EBIT growth 5Y8.6%
EBIT Next Year43.23%
EBIT Next 3Y19.91%
EBIT Next 5Y13.54%
FCF growth 1Y69.65%
FCF growth 3Y2.19%
FCF growth 5Y9.48%
OCF growth 1Y15.52%
OCF growth 3Y1.4%
OCF growth 5Y9.82%

WEST PHARMACEUTICAL SERVICES / WST FAQ

What is the fundamental rating for WST stock?

ChartMill assigns a fundamental rating of 6 / 10 to WST.


What is the valuation status for WST stock?

ChartMill assigns a valuation rating of 3 / 10 to WEST PHARMACEUTICAL SERVICES (WST). This can be considered as Overvalued.


Can you provide the profitability details for WEST PHARMACEUTICAL SERVICES?

WEST PHARMACEUTICAL SERVICES (WST) has a profitability rating of 7 / 10.


Can you provide the financial health for WST stock?

The financial health rating of WEST PHARMACEUTICAL SERVICES (WST) is 8 / 10.


How sustainable is the dividend of WEST PHARMACEUTICAL SERVICES (WST) stock?

The dividend rating of WEST PHARMACEUTICAL SERVICES (WST) is 6 / 10 and the dividend payout ratio is 12.4%.